ZIP9 is a Druggable Determinant of Sex Differences in Melanoma
C. Aguirre-Portoles, R. Payne, A. Trautz, J. K. Foskett, C. A. Natale, J. T. Seykora, T. W. Ridky
The paper identifies ZIP9 as a target of testosterone in melanoma and shows that androgen receptor inhibitors can block ZIP9 to suppress melanoma growth in males.
bioRxiv · Mar 12, 2020Cancer Biology